Cancer immunotherapy: Are we there yet?

Experimental Hematology and Oncology

Volumn 2, Issue 1, 2013, Pages

  Li, Zihai ^a   Chen, Lieping ^b   Rubinstein, Mark P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; IPILIMUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; SIPULEUCEL T; TRASTUZUMAB;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LYMPHOCYTE TRANSFER; MELANOMA; MEMORY T LYMPHOCYTE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; TREATMENT INDICATION; TUMOR IMMUNITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 84978021300     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/2162-3619-2-33     Document Type: Review

References (50)

1. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957, 18:769-778.
2. Klein G. The strange road to the tumor-specific transplantation antigens (TSTAs). Cancer Immun 2001, 1:6.
3. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480(7378):480-489. 10.1038/nature10673, 22193102.
4. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012, 12(4):278-287. 10.1038/nrc3236, 22437872.
5. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112(12):4371-4383. 10.1182/blood-2008-03-077974, 19029455.
6. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, et al. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57(1):7-28. 10.3322/canjclin.57.1.7, 17237032.
7. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children: Taiwan childhood hepatoma study group. N Engl J Med 1997, 336(26):1855-1859. 10.1056/NEJM199706263362602, 9197213.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26):2443-2454. 10.1056/NEJMoa1200690, 3544539, 22658127.
10. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2):122-133. 10.1056/NEJMoa1302369, 23724867.
11. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465. 10.1056/NEJMoa1200694, 3563263, 22658128.
12. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422. 10.1056/NEJMoa1001294, 20818862.
13. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365(8):725-733. 10.1056/NEJMoa1103849, 3387277, 21830940.
14. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368(16):1509-1518. 10.1056/NEJMoa1215134, 23527958.
15. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2013, 118(18):4817-4828.
16. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5(177):177ra138.
17. McCarthy EF. The toxins of William B Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006, 26:154-158. 1888599, 16789469.
18. Hoption Cann SA, Van Netten JP, Van Netten C, Glover DW. Spontaneous regression: a hidden treasure buried in time. Med Hypotheses 2002, 58(2):115-119. 10.1054/mehy.2001.1469, 11812185.
19. Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother 2001, 50(8):391-396.
20. Goldstein MG, Li Z. Heat-shock proteins in infection-mediated inflammation-induced tumorigenesis. J Hematol Oncol 2009, 2:5. 10.1186/1756-8722-2-5, 2644312, 19183457.
21. Burnet M. Cancer; a biological approach: I: the processes of control. Br Med J 1957, 1(5022):779-786. 10.1136/bmj.1.5022.779, 1973174, 13404306.
22. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013, 341(6151):1192-1198. 10.1126/science.1241145, 24031011.
23. DeVita VT, Rosenberg SA. Two hundred years of cancer research. N Engl J Med 2012, 366(23):2207-2214. 10.1056/NEJMra1204479, 22646510.
24. Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, et al. Cancer progress report 2013. Clin Cancer Res 2013, 19(20 Suppl):S4-98.
25. Eggermont AM, Kroemer G, Zitvogel L. Immunotherapy and the concept of a clinical cure. Eur J Cancer 2013, 49(14):2965-2967. 10.1016/j.ejca.2013.06.019, 23890942.
26. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129. 10.1126/science.1129003, 2267026, 16946036.
27. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001, 2(4):293-299. 10.1038/86297, 11276199.
28. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331(6024):1565-1570. 10.1126/science.1203486, 21436444.
29. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208. 10.1146/annurev.immunol.24.021605.090733, 16551247.
30. Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 2013, 13:15. 3718731, 23882160.
31. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010, 3:7. 10.1186/1756-8722-3-7, 2831814, 20146807.
32. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, De Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003, 198(4):569-580. 10.1084/jem.20030590, 2194177, 12925674.
33. Thomas ED. Bone marrow transplantation: a review. Semin Hematol 1999, 36(4 Suppl 7):95-103.
34. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010, 28(28):4390-4399. 10.1200/JCO.2009.27.6360, 2954137, 20697078.
35. Pandey JP, Li Z. The forgotten tale of immunoglobulin allotypes in cancer risk and treatment. Exp Hematol Oncol 2013, 2(1):6. 10.1186/2162-3619-2-6, 3598368, 23425356.
36. Agarwala SS. An update on pegylated IFN-alpha2b for the adjuvant treatment of melanoma. Expert Rev Anticancer Ther 2012, 12(11):1449-1459. 10.1586/era.12.120, 23249109.
37. Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004, 305(5681):197-200. 10.1126/science.1099688, 15247468.
38. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008, 8(6):467-477. 10.1038/nri2326, 18500231.
39. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182(2):459-465. 10.1084/jem.182.2.459, 2192127, 7543139.
40. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271(5256):1734-1736. 10.1126/science.271.5256.1734, 8596936.
41. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992, 71(7):1093-1102. 10.1016/S0092-8674(05)80059-5, 1335364.
42. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12(4):252-264. 10.1038/nrc3239, 22437870.
43. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8(8):793-800.
44. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12(4):269-281. 10.1038/nri3191, 22437939.
45. Riddell SR, Jensen MC, June CH. Chimeric antigen receptor-modified T cells: clinical translation in stem cell transplantation and beyond. Biol Blood Marrow Transplant 2013, 19(1 Suppl):S2-S5.
46. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013, 13(8):525-541. 10.1038/nrc3565, 23880905.
47. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116(20):4099-4102. 10.1182/blood-2010-04-281931, 2993617, 20668228.
48. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013, 39(1):49-60. 10.1016/j.immuni.2013.07.002, 23890063.
49. Li Y, Zeng H, Xu RH, Liu B, Li Z. Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. Stem Cells 2009, 27(12):3103-3111.
50. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.